Tevogen Bio (TVGN) Stock Price, News & Analysis

Company Overview

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and cancer. The company’s approach uses antigen-specific cytotoxic T lymphocytes designed to recognize and eliminate infected or abnormal cells while seeking to provide an “off-the-shelf” treatment option.

Tevogen’s pipeline is built around its ExacTcell platform, which is intended to support the development and manufacturing of targeted cellular immunotherapies. Its lead program, TVGN 489, is an investigational, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19. The therapy is not approved for commercial use.

Tevogen was founded by physician and biotechnology executive Dr. Ryan Saadi, who serves as the company’s chairman and chief executive officer. The company is based in Warren, New Jersey, and is developing therapies for potential use in the United States and other markets, subject to clinical development and regulatory approvals. Tevogen became a publicly traded company through a business combination with Semper Paratus Acquisition Corporation.

Key Stats

• Today's Range: $6.59 to $7.01
• 50-Day Range: $5.57 to $7.85
• 52-Week Range: $3.64 to $39.50
• Volume: 1,618 shs
• Average Volume: 8,360 shs
• Market Capitalization: $45.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.00
• Consensus Rating: Reduce

Tevogen Bio Stock Analysis - MarketRank™

Tevogen Bio scored higher than 25% of companies evaluated by MarketBeat, and ranked 770th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Tevogen Bio has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Tevogen Bio has a consensus price target of $100.00, representing about 1,332.7% upside from its current price of $6.98.

Amount of Analyst Coverage

Tevogen Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Tevogen Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tevogen Bio is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.60% of the float of Tevogen Bio has been sold short.

Short Interest Ratio / Days to Cover

Tevogen Bio has a short interest ratio ("days to cover") of 5.23.

Change versus previous month

Short interest in Tevogen Bio has recently decreased by 2.98%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tevogen Bio does not currently pay a dividend.

Dividend Growth

Tevogen Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tevogen Bio this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Tevogen Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

65.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Tevogen Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/04/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TVGN
• Previous Symbol: NASDAQ:TVGN
• CIK: 1860871
• Web: www.tevogen.com
• Phone: (646) 807-8832
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tevogen Bio: $100.00
• High Price Target: $100.00
• Low Price Target: $100.00
• Potential Upside/Downside: +1,332.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -468.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.33
• Quick Ratio: 0.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($211.84) per share
• Price / Book: -0.03

Miscellaneous

• Outstanding Shares: 6,510,000
• Free Float: 2,240,000
• Market Cap: $45.44 million
• Optionable: N/A
• Beta: 0.19